Patient Safety Movement Foundation Welcomes New Leadership
21.10.2021 15:00:00 EEST | Business Wire | Press release
The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, today announced Michael A.E. Ramsay, MD, FRCA as its new chief executive officer. Following his appointment, Mike Durkin, OBE, MBBS, FRCA, FRCP, DSc will assume Ramsay’s previous role as chairman. Under their leadership, the organization looks forward to continuing to improve patient safety around the globe.
Dr. Ramsay assumes the role from former CEO, David B. Mayer, MD, who played a pivotal part in helping the organization launch the inaugural #UniteForSafeCare event. During his tenure, Mayer also introduced a new commitment model making it easier for hospitals and healthcare organizations to prioritize patient safety and was a driving force behind the call for a Patient Safety Moonshot.
“We are grateful for all of Dr. Mayer’s efforts over the past three years and believe that Dr. Ramsay is the right leader for this next chapter,” stated Ariana Longley, MPH, chief operating officer at the Patient Safety Movement Foundation. “The leadership, expertise, passion and global connections that Dr. Ramsay and Dr. Durkin bring to the organization position us well to achieve our audacious goals.”
“I am honored to be appointed as CEO,” said Dr. Ramsay. “The last year and a half has put a spotlight on the gaps in our healthcare system. I am excited to work in lockstep with the strong leadership and team at PSMF to forge partnerships that actively promote change, develop and disseminate patient safety education material and create public demand for safe and highly reliable healthcare.”
Prior to being named CEO, Dr. Ramsay was an early member of PSMF set up by Joe Kiani in 2012 and most recently served as chairman of PSMF since 2020. He brings extensive experience serving as chairman emeritus of the Department of Anesthesiology and Pain Management at Baylor University Medical Center in Dallas, Texas. He is also a professor at the Texas A&M Health Science Center and holds a clinical professorship in anesthesiology at the University of Texas Southwestern Medical School. Ramsay was president of the Baylor Scott and White Research Institute from 2000 to 2020, where the focus was on developing cancer vaccines and early cancer biomarkers. He is past director of anesthesia for the liver transplant program at Baylor and has personally provided anesthesia for over 1,000 liver transplant recipients. He has also held roles in numerous groups, including a current member of the Baylor University Medical Center board of trustees, past president of the International Liver Transplantation Society, committee member of the United Network for Organ Sharing and a member of the American Society of Anesthesiologists committee on transplant anesthesia and “Failure to Rescue: Post-operative Respiratory Depression” workgroup of the PSMF. He was born in Dublin, Ireland, went to Brentwood School in the UK and trained in medicine at The Royal London Hospital. Ramsay was recruited by Baylor University Medical Center in Dallas, Texas in 1976.
Dr. Durkin has been a member of PSMF since 2012 and is transitioning from vice chairman to chairman. Durkin brings 30 years of experience in medical management and leadership to his role with PSMF. He currently maintains positions as the visiting professor and senior advisor on patient safety policy and leadership of the NIHR Patient Safety Translational Research Centre at the Institute of Global Health Innovation at Imperial College London and as associate non-executive director at NHS Resolution. Passionate about patient safety, he played an integral role in the assembly of the Berwick Advisory Board in 2013 to advise on creating conditions to improve the safety of patients in England. Durkin was commissioned by the secretary of state for health to chair an expert advisory group that led to the establishment of the Healthcare Safety Investigation branch. He also headed the development of the Ministerial Inter-Governmental Summits on Patient Safety held in the UK (2016), Germany (2017), Japan (2018) and Saudi Arabia (2019). Outside of PSMF, he has served as the national director of patient safety for England’s NHS, executive medical director at Gloucestershire Royal Hospital and held successive executive medical director positions for England’s strategic health authorities culminating as the medical director of the NHS for the South of England supporting a population of 16 million people. Prior to these roles, he held attending, research and teaching positions in cardiovascular anesthesia and critical care at London, Yale and Bristol universities.
“I am honored to continue to work with the Patient Safety Movement Foundation in this role,” states Durkin. “We have made great progress but are now at a time when we must issue a call to urgent and sustained action for all patients and families as well as political and healthcare leaders, nurses, doctors, pharmacists and therapists of every dimension to continue to educate and empower others to help us reach our goal of zero.”
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org, and follow PSMF on LinkedIn, Twitter, Instagram and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005331/en/
Contact information
MEDIA CONTACT:
Leslie Licano, Beyond Fifteen Communications, Inc.
psmf@beyondfifteen.com | (949) 733-8679 ext.101
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Cutting-Edge Research to Industry: Focused Energy Plans Spin-Off of Sourcelight10.6.2026 12:38:00 EEST | Press release
Following its successful USD 240 million financing round, Focused Energy is continuing to systematically advance the industrialization of laser fusion as its core business. At the same time, the company plans to consolidate its activities in the field of laser-driven radiation sources into an independent entity under the name Sourcelight. With this move, Focused Energy is laying the groundwork for the industrial transfer of selected technological building blocks emerging from its laser fusion development. The spin-off demonstrates how cutting-edge research can give rise to new industry: scientific excellence is translated into industrial applications with strong value creation and growth potential. Sourcelight is intended to bring the LDRS (Laser-Driven Radiation Sources) technology developed by Focused Energy into targeted industrial applications. The technology combines laser-driven high-energy X-rays and neutrons in a single system. This enables not only high-resolution imaging, but
Cosylab and Heron Neutron Medical Corp. Sign Letter of Intent to Advance Global Deployment of Accelerator-Based BNCT Systems10.6.2026 12:30:00 EEST | Press release
Cosylab and Heron Neutron Medical Corp. announced today, 10 June 2026, the signing of a Letter of Intent to establish a strategic framework for joint market development to support the global deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems. The collaboration aims to accelerate the development and integration of sophisticated software solutions for use with AB-BNCT while strengthening AB-BNCT's international market access and business development. By combining Cosylab's proven expertise in mission-critical software and complex system integration with Heron's end-to-end BNCT platforms, the partnership aims to drive broader global clinical adoption of this highly targeted cancer treatment modality. "AB-BNCT is emerging as one of the most promising approaches for treating difficult-to-treat and recurrent cancers," said Mark Pleško, Chief Executive Officer of Cosylab. "This collaboration reinforces our strategic focus on advancing radiation therapy technologie
GlobalFoundries and Qualinx Demonstrate First European Sovereign Manufacturing Flow for Security‑Critical Semiconductors10.6.2026 12:25:00 EEST | Press release
GlobalFoundries (GF) and Qualinx today announced the successful completion of the first fully European-based, end-to-end semiconductor manufacturing flow at GlobalFoundries’ Dresden fab on its FDX technology. The milestone demonstrates that security-critical chips for aerospace, defence and critical infrastructure can be designed, manufactured and delivered entirely within Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610196220/en/ In this partnership, Qualinx served as the launch customer with a sophisticated GNSS SoC design for secure Positioning, Navigation and Timing (PNT) applications. The QLX3xx design targets sovereign GNSS-based PNT solutions for aerospace, defence and critical infrastructures—such as resilient timing and synchronization networks and highly integrated, ultra-low-power GNSS receivers at the connected edge. GF and Qualinx Set a Benchmark for GF’s European Sovereign Manufacturing co-funded b
LTM Introduces BlueVerse™ Currency to Enable Outcome-Based Pricing in the Agentic AI Era10.6.2026 11:30:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today introduced BlueVerse™ Currency, an AI-linked commercial model that prices enterprise work by outcomes rather than effort consumed as enterprises scale agentic AI across core processes. BlueVerse Currency brings together the full BlueVerse stack—People (expertise on demand), Accelerators (reusable assets that speed delivery), Agents (autonomous AI workforce), Platforms (orchestration layer to scale delivery), and Tokens (compute and model usage)—into a single commercial construct. It introduces outcome-linked pricing tied to measurable business results, enabling shared productivity gains so clients can capture AI-driven efficiency value. The model also supports fungible resourcing, enabling reallocation mid-contract to evolving priorities, and faster reinvestment, with savings redirected into innovation. It is underpinned by a hybrid structure with fixed and variable pricing components, supported by use-case–
Smead Capital Management Extends International Value Strategy to Global Investors Through New Fund10.6.2026 10:00:00 EEST | Press release
Smead Capital Management, a Phoenix-based investment management firm and a leader in value investing, today announced the launch of the Smead Global ex-US Value UCITS Fund designed to provide global investors with access to a product modeled after the firm’s long-standing Smead International Value Strategy. The Smead Global ex-US Value UCITS Fund is domiciled in Luxembourg. Investors can access the fund through Smead Capital Management’s website and it is available to professional and qualified investors through the fund’s transfer agent. The strategy that the Smead Global ex-US Value UCITS Fund is modeled after, the Smead International Value Strategy, has been a core contributor to Smead Capital Management’s outstanding performance for over a decade. Like all Smead products, the Global ex-US Value UCITS Fund will be built on Smead’s eight investment criteria and a disciplined, contrarian, value approach. “Many investors around the world believe non-US companies cannot produce attracti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
